Detection of costimulatory molecules in hematologic malignant tumors and its clinical significance

马肖容,张王刚,曹星梅,何爱丽,刘捷,田玮,张慧
DOI: https://doi.org/10.3969/j.issn.1671-8259.2003.04.010
2003-01-01
Abstract:Objective: To explore the significance of costimulatory molecule B7-1 (CD80) and MHC molecules in the pathogenesis of hematologic malignant tumors and in the immuno-genetic therapy. Methods: The expression of costimulatory molecule B7-1 and MHC I, and MHC II DR molecules was detected by immunofluoressence in 76 cases of hematologic malignant tumors. Moreover, it was compared with the effects of active immunotherapy by the auto vaccine. Results: MHC class I molecule was positive (100%) in all cases and the positive rate of MHC II DR molecule was 95%. The rate of B7-1 molecule was higher in acute mononcytic leukemia (M5) and multiple myeloma (MM) (69% and 100%, respectively). However, it was lower in myeloid leukemia. Furthermore, it supported the clinical effects of recent active specific immunotherapy with an auto vaccine. In the cases which responded well to immunotherapy such as M5 and MM, B7-1 was positive. Conclusion: The deficiency of costimulatory molecules (such as B7-1) is an important cause for leukemic tumor cells evading host immunosurveillance and may be one of the mechanisms of human hematologic malignant tumors. It is also indicated that immuno-genetic therapy mediated by B7-1 may be an effective way against human hematologic malignant tumors and has a significant clinical value.
What problem does this paper attempt to address?